A Study of LGD-6972 in Patients With Type 2 Diabetes Mellitus

ClinicalTrials.gov ID: NCT02851849

Public ClinicalTrials.gov record NCT02851849. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 10, 2026, 8:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Safety and Efficacy of LGD-6972 in Patients With Type 2 Diabetes Mellitus

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the change from baseline in hemoglobin A1c (HbA1c) during 12 weeks of treatment with 3 dose levels of LGD-6972 compared to placebo in subjects with Type 2 Diabetes Mellitus (T2DM)

Study identification

NCT ID: NCT02851849
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Ligand Pharmaceuticals; Industry
Enrollment: 148 participants

Conditions and interventions

Conditions

Type 2 Diabetes Mellitus

Interventions

Drug · Other

Eligibility (public fields only)

Age range: 21 Years to 70 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 31, 2016
Primary completion: May 31, 2017
Completion: May 31, 2017
Last update posted: Jan 11, 2018

2016 – 2017

United States locations

U.S. sites: 29
U.S. states: 14
U.S. cities: 27

Facility	City	State	ZIP	Site status
Not listed	Tuscumbia	Alabama	35674	—
Not listed	Chandler	Arizona	85224	—
Not listed	Surprise	Arizona	85374	—
Not listed	Huntington Park	California	90255	—
Not listed	Los Angeles	California	90057	—
Not listed	Montclair	California	91763	—
Not listed	North Hollywood	California	91606	—
Not listed	San Diego	California	92161	—
Not listed	Denver	Colorado	80209	—
Not listed	Brooksville	Florida	34601	—
Not listed	Miami	Florida	33014	—
Not listed	Orlando	Florida	32804	—
Not listed	Tampa	Florida	33607	—
Not listed	Chicago	Illinois	60607	—
Not listed	Las Vegas	Nevada	89119	—
Not listed	Albuquerque	New Mexico	87102	—
Not listed	Hopewell Junction	New York	12533	—
Not listed	Durham	North Carolina	27710	—
Not listed	Greensboro	North Carolina	27410	—
Not listed	Franklin	Ohio	45005	—
Not listed	Munroe Falls	Ohio	44262	—
Not listed	Summerville	South Carolina	29485	—
Not listed	Carrollton	Texas	75007	—
Not listed	Dallas	Texas	75230	—
Not listed	Houston	Texas	77036	—
Not listed	Houston	Texas	77074	—
Not listed	Houston	Texas	77099	—
Not listed	Katy	Texas	77450	—
Not listed	Manassas	Virginia	20110	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02851849, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jan 11, 2018 · Synced Sep 10, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02851849 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →